Table 6.
Summary of costs and benefits of afatinib vs PemCis - base-case analysis
| Afatinib | Pemetrexed-cisplatin | Incremental difference | |
|---|---|---|---|
| Total cost (SG$) | 93,958 | 78,731 | 15,227 |
| Cost of PF state | 44,205 | 11,236 | 32,969 |
| Cost of PD state | 49,548 | 67,401 | −17,853 |
| Cost of AE | 205 | 94 | 111 |
| Total benefit | |||
| QALYs | 1.69 | 1.58 | 0.11 |
| LYs | 2.59 | 2.45 | 0.14 |
| PFLYs | 1.18 | 0.68 | 0.50 |
| ICER (QALY) | – | – | 137,648 |
| ICER (LY) | – | – | 109,172 |
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, LY life year, PFLY progression-free life year, AE adverse event, PF progression-free, PD progressed disease